

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (fg-150) LIFIRAFENIB MALEATE


PRONUNCIATION li fir ra fen' ib

THERAPEUTIC CLAIM Antineoplastic

CHEMICAL NAMES

- 1,8-Naphthyridin-2(1*H*)-one, 5-[[[(1*R*,1*aS*,6*bR*)-1*a*,6*b*-dihydro-1-[6-(trifluoromethyl)-1*H*-benzimidazol-2-yl]-1*H*-cyclopropa[*b*]benzofuran-5-yl]oxy]-3,4-dihydro-, (2*Z*)-2-butenedioate (2:3)
- 5-(((1*R*,1*aS*,6*bR*)-1-[5-(trifluoromethyl)-1*H*-benzimidazol-2-yl]-1*a*,6*b*-dihydro-1*H*-cyclopropa[*b*][1]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1*H*)-one—maleic acid (2:3)

STRUCTURAL FORMULA



MOLECULAR FORMULA  $C_{25}H_{17}F_3N_4O_3 \cdot C_6H_6O_6$

MOLECULAR WEIGHT 652.5

TRADEMARK None as yet

SPONSOR BeiGene USA, Inc.

CODE DESIGNATIONS BGB-283 sesqui-maleate

CAS REGISTRY NUMBER 1854985-74-2

UNII 9VU33DC00T

gbk